- Home
- GMAB
GMAB
Genmab A/S ADS
as 04-02-2025 4:00pm EST
| Founded: | 1999 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $40.00 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 16.85 | EPS Growth: | 83.82 |
| 52 Week Low/High: | $18.48 - $30.50 | Next Earning Date: | 05-01-2025 |
| Revenue: | $2,988,286,182 | Revenue Growth: | 30.67% |
| Revenue Growth (this year): | 19.81% | Revenue Growth (next year): | 13.94% |
Latest Genmab A/S ADS News
GMAB Breaking Stock News: Dive into GMAB Ticker-Specific Updates for Smart Investing
Insider Monkey
14 hours ago
Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?
GlobeNewswire
a day ago
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Insider Monkey
2 days ago
Is Genmab A/S (GMAB) the Most Undervalued Healthcare Stock to Buy According to Analysts?
MT Newswires
2 days ago
Genmab Says European Commission Grants Marketing Authorization for Tivdak as Cervical Cancer Treatment
Business Wire
3 days ago
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
GlobeNewswire
3 days ago
Transactions in connection with share buy-back program
Pharmaceutical Technology
6 days ago
Genmab’s Tivdak approved in Japan for advanced cervical cancer
Benzinga
6 days ago
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
Compare GMAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GMAB Genmab A/S ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.